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1Introduction
Worldwide, 90,000 [1] allogeneic HSCTs were performed 
between 2001 and 2011, with 4369 [2] of these procedures 
occurring in Australia. With improvements in donor selec-
tion, conditioning therapies, and supportive care, 35–80% 
of HSCT recipients can now be expected to become long- 
term survivors and be cured of their underlying disease 
[3]. While HSCT provides a clear benefit for many patients 
with malignant and nonmalignant disease, it is also asso-
ciated with significant morbidity and mortality [4].
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Abstract
In addition to prescribed conventional medicines, many allogeneic hematopoietic 
stem cell transplant (HSCT) survivors also use complementary and alternative 
medical therapies (CAM), however, the frequency and types of CAMs used by 
allogeneic HSCT survivors remain unclear. Study participants were adults who 
had undergone an allogeneic HSCT between 1st January 2000 and 31st December 
2012. Participants completed a 402- item questionnaire regarding the use of 
CAM, medical complications, specialist referrals, medications and therapies, 
infections, vaccinations, cancer screening, lifestyle, and occupational issues and 
relationship status following stem cell transplantation. A total of 1475 allogeneic 
HSCT were performed in the study period. Of the 669 recipients known to be 
alive at study sampling, 583 were contactable and were sent study packs. Of 
432 participants who returned the completed survey (66% of total eligible, 76% 
of those contacted), 239 (54.1%) HSCT survivors used at least one form of 
CAM. These included dietary modification (13.6%), vitamin therapy (30%), 
spiritual or mind–body therapy (17.2%), herbal supplements (13.5%), manipula-
tive and body- based therapies (26%), Chinese medicine (3.5%), reiki (3%), and 
homeopathy (3%). These results definitively demonstrate that a large proportion 
of HSCT survivors are using one or more form of CAM therapy. Given the 
potential benefits demonstrated by small studies of specific CAM therapies in 
this patient group, as well as clearly documented therapies with no benefit or 
even toxicity, this result shows there is a large unmet need for additional studies 
to ascertain efficacy and safety of CAM therapies in this growing population.
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In recent years, there has been growing literature on 
the long- term (or late) psychosocial and medical com-
plications experienced by HSCT survivors. The impact of 
these is profound with HSCT survivors experiencing a 
30% lower life expectancy than a matched population 
cohort [4]. While many survivors rate their quality of 
life highly at 2 years posttransplant, many HSCT recipients 
experience considerable difficulty coping with the short- , 
medium- , and long- term physical and psychological seque-
lae of HSCT and with the uncertainties of their prognosis. 
Given the extent and impact of late complications of 
HSCT, ongoing long- term follow- up and multidisciplinary 
care of HSCT recipients is essential [5].
In addition to prescribed conventional medicines, many 
HSCT survivors also use complementary and alternative 
medical therapies (CAM). However, the prevalence and 
extent of the usage of CAMs in this patient group remains 
unclear. A review published in 1998 found the prevalence 
of CAM use among cancer patients ranges from 7% to 
64% of patients sampled in 26 studies conducted world-
wide [6]. This is consistent with CAM use in the general 
population, estimated at 40% in Australia, Canada, Europe, 
New Zealand, and the United States [7].
Studies in the United States have reported that the 
most common complementary practices and products used 
by individuals with cancer are vitamin/mineral supple-
ments, prayer for self, intercessory prayer, chiropractic/
osteopathic manipulation, and herbal therapies [8]. To 
date, no studies have reported CAM usage by HSCT 
patients.
Despite the lack of literature on the epidemiology of 
CAM use in HSCT patients, there have been a number 
of small trials, including randomized controlled studies 
showing a potential benefit for some CAM therapies such 
as mind and body interventions, although the majority 
of CAM treatments show inconclusive mixed results [9]. 
The authors of a recent literature review of these known 
studies of CAMs in HSCT proposed that a current barrier 
to the use and research in CAM therapy is the recogni-
tion and acceptance of CAM use in this population and 
that epidemiologic estimates were required [9]. The aim 
of this study was to describe the frequency and types of 
CAM used by HSCT survivors, with the intention of 
enhancing recognition of CAM use.
Methods
Patients and procedures
Study participants were eligible if they were >18 years of 
age and had undergone an allogeneic HSCT between 1st 
January 2000 and 31st December 2012 in New South 
Wales (NSW) (NSW is Australia’s most populous state 
– with a population of ~7.5 million [10]), and could 
read and write English. Potential participants were identi-
fied from the transplant databases of all allogeneic trans-
plant centers in NSW, with names and phone numbers 
provided to the research team. Consenting participants 
were given the option to self- complete the questionnaire 
or to complete it via a phone interview with one of the 
researchers. A second round of telephone calls was made 
to consenting participants who had not returned the survey 
within a month. The study protocol was approved by 
the Northern Sydney Coast Human Research Ethics 
Committee (NSLHD Reference: 1207–217M).
Instruments
The Sydney Post HSCT Study survey (SPBS) was developed 
by the research team. Item construction was informed by 
a review of the literature and discussions with patients 
attending HSCT long- term follow- up clinics. It consisted 
of 402 questions, including questions relating to the use 
of CAMs, specifically: Nutrition and Dietary approaches, 
Herbal supplements, Vitamin therapies, Mind–Body thera-
pies (e.g., Meditation), Manipulative and Body therapies 
(e.g., Acupuncture), Traditional medicine (e.g., Traditional 
Chinese Medicine), Energy medicine (e.g., Reiki), and 
Homeopathy. Other relevant domains included demographic 
data, medical complications, specialist referrals, tests and 
assessments, medications and therapies, infections, vaccina-
tions, cancer screening, close personal contacts, lifestyle, 
occupation, and relationship status following stem cell 
transplantation. The questionnaire used tick box response, 
short answer questions, and 5- step Likert scales measuring 
attitudes and other factors, and takes approximately 1 h 
to complete. The questionnaire was piloted in clinic and 
phone interviews to assess face and content validity and 
to check for comprehension of the survey questions.
An additional one page HSCT clinical data form (The 
Sydney Post HSCT Clinical Data Form) was used to col-
lect information from the transplant database including 
date of transplant, date of diagnosis, stage at transplant, 
transplant conditioning, Graft- versus- Host Disease (GvHD) 
prophylaxis, stem cell source, and donor type.
Measures
Participants were classified as CAM users if they used at 
least one therapy in any of the CAM categories. CAM 
use was correlated with demographics, medical complica-
tions, posttransplant medical therapies, treatments and 
clinical variables, relationship status, and social determi-
nants including income and occupational status. The 
relationship of CAM use was further explored against a 
range of survey instruments that measured quality of life 
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(Functional Assessment of Cancer Therapy – Bone Marrow 
Transplant (FACT- BMT Version 4), anxiety, stress, and 
depression (The DASS 21), chronic GVHD (The Chronic 
GVHD Activity Assessment – Patient Self Report (Form 
B) and The Lee Chronic GVHD Symptom Scale), and 
an assessment of life change in response to traumatic 
events (The Post Traumatic Growth Inventory score).
Statistical considerations
Categorical responses were summarized using frequencies 
and percentages. Parametric continuous variables were 
summarized using means and standard deviations, and 
nonparametric variables using medians and interquartile 
ranges. The Pearson’s X 2 test or Fishers Exact tests were 
used for comparative analysis of dichotomous categorical 
variables. Two sample comparisons of means and medians 
were determined using the independent t test and Wilcoxon 
Rank Sum tests, respectively; greater than two sample 
comparisons of means and medians were determined using 
one- way analysis of Variance (ANOVA) and Kruskal–Wallis 
tests, respectively. A two- tailed P < 0.05 was used as the 
level of statistical significance.
Results
Study subjects
A total of 1475 Allogeneic HSCT were performed in the 
study period. Of the 669 recipients known to be alive at 
study sampling, 583 were contactable and were sent study 
packs. A total of 432 (66% of total eligible, 76% of those 
contacted) returned the completed survey. Three percent 
declined participation.
Transplantation details
Median survival time post- HSCT was 5 years (range: 1 year 
4 months–22 years). The main indication for transplanta-
tion was acute leukemia (AML/ALL) in 226 (52.3%). 
Remission status was reported in 406 HSCT, of which 
271 (66.8%) were CR1 or CR2. Donor type was reported 
in 432 transplant procedures of which the majority were 
siblings (57.1%) and matched unrelated donors (35.8%). 
Peripheral blood stem cells were used in 381 (88.1%) of 
transplants. Myeloablative conditioning regimens were used 
in 216 (50.0%) and of these 103 (47.7%) employed total 
body irradiation (TBI). T- cell depleting therapy was 
reported in 122 (28.2%). Antithymocyte globulin (ATG) 
accounted for 92.6% of T- depleting modalities, with 
Alemtuzumab accounting for 3.3%.
Usage of complementary and alternative 
medicine therapies
A total of 239 (54.2%) of HSCT survivors used at least 
one form of CAM, including dietary modification (13.4%), 
vitamin therapy (including minerals and oils) (29.3%), 
spiritual and mind–body therapy (17.2%), herbal supple-
ments (13.2%), manipulative and body- based therapies 
(25.4%), Chinese medicine (3.4%), reiki (3%), and home-
opathy (3%) (Table 1). One hundred and seventeen (27.2%) 
patients used more than one form of CAM, ranging up 
to seven forms of CAM (Table 2).
Characteristics of CAM users are shown in Table 3. 
There was no age difference between CAM users and 
nonusers. Women (P = 0.019), people living in a major 
city (P = 0.017), those with a university education 
(P = 0.001), and those with bone disease (P = 0.029) 
were significantly more likely to use at least one CAM. 
When comparing pretransplant diagnosis, type of condi-
tioning or time from transplant, cGvHD, diabetes, car-
diovascular risk, thyroid problems, anxiety, and depression, 
no difference in CAM use was seen.
Additionally, patients taking antibacterial, antiviral, or 
antifungal treatment were significantly less likely to use 
CAMs (P = 0.041), whereas patients taking other prescrip-
tion drugs, including immunosuppressant, cardiovascular, 
hormone replacement, or psychotropic medications, were 
no more or less likely to use CAMs. Patients who rou-
tinely saw a Psychologist (P = 0.024) or Physiotherapist 
(P = 0.010) were more likely to use CAMs, as were those 
who did regular exercise (P = 0.049). There was no 
Table 1. Total complementary and alternative medical therapies (CAM) 
usage.
Overall CAM users 54.2% (239)
Dietary modification 13.6% (59)
Vitamin therapy (ex Calcium/Vit D) 27.3% (109)
Mind–body therapy (inc spiritual) 17.2% (74)
Herbal supplementation 13.5% (58)
Manipulative and body- based therapies 26.0% (112)
Chinese medicine 3.5% (15)
Reiki 3.0% (13)
Homeopathy 3.0% (13)
Table 2. Total complementary and alternative medical therapies (CAM) burden.
Number of CAMs Nil At least 1 1 2 3 4 5 6 7
Patients 43.8% (193) 54.2% (239) 26.0% (116) 14.5% (62) 6.6% (27) 4.3% (17) 0.9% (4) 0.9% (4) 0.7% (3)
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Table 3. Characteristics of CAM users.
Variables CAM users (%) Nonusers (%) P value OR (CI)
Demographic
Gender 0.019 0.63 (0.42–0.92)
Male (n = 244) 123/239 (51.5) 121/193 (62.7)
Female (n = 188) 116/239 (48.5) 72/193 (37.3)
Age (years) 0.73 1.06 (0.73–1.56)
<54 (n = 221) 124/239 (51.9) 97/193 (50.3)
≥54 (n = 211) 115/239 (48.1) 96/193 (49.7)
Postcode 0.017 1.68 (1.0–2.5)
City – metro (n = 305) 180/234 (76.9) 125/188 (66.5)
Regional or remote (n = 117) 54/234 (23.1) 63/188 (33.5)
Socioeconomic
Education
Some high school (n = 53), completed high school 
(n = 78), Trade/diploma (n = 44), Some university 
(n = 24), completed university (n = 126)
0.018 –
University education (n = 150) 98/179 (54.7) 52/146 (35.6) 0.001 2.18 (1.36–3.42)
Other (n = 175) 81/179 (45.3) 94/146 (64.4)
Posttransplant income 0.43 0.85 (0.57–1.27)
Low income (n = 153) 81/230 (35.2) 72/185 (38.9)
Middle- high income (n = 262) 149/230 (64.8) 113/185 (61.1)
Occupational status
Full/Part time (n = 211) 118/220 (53.6) 93/194 (47.9) 0.24 1.25 (0.85–1.85)
Unemployed, Retired or Casual ( n = 203) 102/220 (46.4) 101/194 (52.1)
Transplant factors
Pretransplant cancer diagnosis 0.78 1.05 (0.71–1.55)
Acute leukemia (n = 219) 122/228 (53.5) 97/186 (52.2)
Other (n = 195) 106/228 (46.5) 89/186 (47.8)
Years since transplant N = 239 N = 193 0.053 –
<2 years (n = 57) 27 (11.3) 30 (15.5)
2 < 6 years (n = 199) 105 (43.9) 94 (48.7)
6 < 10 years (n = 115) 64 (26.8) 51 (26.4)
≥10 years (n = 61) 43 (18) 18 (9.3)
Conditioning 0.213 –
Myeloablative (n = 216) 239 193
Reduced intensity (n = 225) 122 (51) 88 (45.6)
Missing (n = 2) 115 (48.1) 105 (54.5)
Clinical factors
cGvHD N = 233 N = 192 0.39 1.23 (0.82–1.87)
Yes (n = 294) 166 (71.2) 128 (66.7)
No (n = 131) 67 (28.8) 64 (33.3)
Diabetes N = 209 N = 180 0.75 0.91 (0.51– 1.6)
Yes (n = 56) 29 (13.9) 27 (15)
No (n = 333) 180 (86.1) 153 (85)
Thyroid N = 205 N = 176 0.40 1.50 (0.57–3.9)
Yes (n = 19) 12 (5.9) 7 (4.0)
No (n = 362) 193 (94.1) 169 (96.0)
CV Risk N = 219 N = 186 0.49 1.14 (0.77–1.70)
Yes (n = 175) 98 (44.7) 77 (41.4)
No (n = 230) 121 (55.3) 109 (58.6)
Self- reported anxiety or depression N = 215 N = 185 0.142 1.38 (0.89–2.15)
Yes (n = 1160 69 (32.1) 47 (25.4)
No (n = 284) 146 (67.9) 138 (74.6)
Bone disease N = 214 N = 178 0.029 1.62 (1.04–2.52)
Yes (n = 121) 76 (35.5) 45 (25.3)
No (n = 271) 138 (64.5) 133 (74.7)
(Continues)
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Variables CAM users (%) Nonusers (%) P value OR (CI)
Skin/Mouth cancers N = 215 N = 183 0.59 1.13 (0.71–1.85)
Yes (n = 94) 53 (24.7) 41 (22.4)
No (n = 304) 162 (75.3) 142 (77.6)
Other medication use
Med group 1 (penicillin, antiviral drug, bactrim, antifungal 
drug)
N = 239 N = 193 0.041 0.66 (0.45–0.98)
Yes (n = 176) 87 (36.4) 89 (46.1)
No (n = 256) 152 (63.6) 104 (53.9)
Med group 2 (immune drug, prednisolone) N = 239 N = 193 0.31 0.81 (0.54–1.21)
Yes (150) 78 (32.6) 72 (37.3)
No (282) 161 (67.4) 121 (62.7)
Med group 3 (any blood pressure drug) N = 239 N = 193 0. 16 0.73 (0.47–1.13)
Yes (107) 53 (22.2) 186 (77.8)
No (325) 54 (28) 139 (72)
Med group 4 (antidepressant, any sleeping tablet, antianxiety 
drug)
N = 239 N = 193 0.50 1.17 (0.73–1.88)
Yes (89) 52 (21.8) 187 (78.2)
No (343) 37 (19.2) 156 (80.8)
Calcium N = 239 N = 193 0.27 1.23 (0.84–1.50)
Yes (205) 119 (49.8) 86 (44.6)
No (227) 120 (50.2) 107 (55.4)
Vitamin D N = 239 N = 193 0.43 1.16 (0.79 –1.7)
Yes (244) 139 (58.2) 105 (54.4)
No (188) 10 (41.8) 88 (45.6)
Bone strengthening drug N = 239 N = 193 0.41 1.25 (0.73–2.14)
Yes (65) 39 (16.3) 26 (13.5)
No (367) 200 (83.7) 167 (86.5)
Med Group 5 (hormonal replacement) N = 239 N = 193 0.116 1.55 (0.89–2.73)
Yes (62) 40 (16.7) 22 (11.4)
No (370) 199 (83.3) 171 (88.6)
Psychosocial
Psychiatrist N = 220 N = 181 0.99 0.99 (0.47–2.08)
Yes (n = 31) 17 (7.7) 14 (7.7)
No (n = 370) 203 (92.3) 167 (92.3)
Psychologist N = 221 N = 185 0.024 1.82 (1.07–3.09)
Yes (n = 74) 49 (22.2) 25 (13.5)
No (n = 332) 172 (77.8) 160 (86.5)
Social worker N = 221 N = 183 0.21 1.4 (0.79–2.67)
Yes (n = 51) 32 (14.5) 19 (10.4)
No (n = 353) 189 (85.5) 164 (89.6)
Dietician N = 222 N = 185 1.00 1.0 (0.63–1.57)
Yes (n = 99) 54 (24.3) 45 (24.3)
No (n = 308) 168 (75.7) 140 (75.7)
Physiotherapist N = 220 N = 183 0.010 1.8 (1.1–3.0)
Yes (n = 97) 64 (29.1) 33 (18)
No (n = 306) 156 (70.9) 150 (82)
Exercise physiologist N = 218 N = 182 0.067 2.0 (0.93–4.3)
Yes (n = 33) 23 (10.6) 10 (5.5)
No (n = 367) 195 (89.4) 172 (94.5)
Lifestyle
BMI group N = 239 N = 193 0.519 –
Normal (193) 112 (46.9) 81 (42)
Obesity (66) 36 (15.1) 30 (15.5)
Overweight (125) 66 (27.6) 59 (30.6)
Underweight (13) 9 (3.8) 4 (2.1)
Missing (35) 
Median (IQR)
Median 24.48  
 (22.1–28.03)
Median 25.1  
 (22.5–28.3)
Table 3. Characteristics of CAM users. (Continued)
(Continues)
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significant relationship with FACT- BMT and patients’ use 
of CAMs.
Dietary modification
Fifty- Nine (13.6%) HSCT survivors modified their diet 
in some way, including caloric supplementation (3; 0.7%), 
low calorie diet (6; 1.4%), gluten- free diet (6; 1.4%), 
lactose- free diet (3; 0.7%), probiotic usage (4; 0.9%), low 
carbohydrate diet (2; 0.5%), vegetarian or pescetarian diet 
(8; 1.8%), low cholesterol diet (4; 0.9%), and use of 
organic food (14; 3.2%). Women were more likely to 
make modifications to their diet post- HSCT than men, 
with 32 (17%) of women and 27 (11%) of men (Male: 
OR: 0.59 [0.34–1.03]). Nine HSCT survivors consulted a 
dietician (2%).
Diagnosis, comorbidities (diabetes mellitus, cardiovascular 
disease), bone disease, and posttransplant cancer diagnosis 
were not significantly associated with dietary modification. 
Those using dietary modification were significantly more 
likely to be further out from their transplant date (median 
6.6 years compared to 5.0 years [P = 0.04]) and reported 
significantly higher FACT- BMT scores (Median 109, IQR 
99–121), indicative of better quality of life.
Herbal therapy
Herbal therapies were uncommonly used by HSCT survi-
vors, with the most common therapies including Ginseng 
(5; 1.1%) and Garlic (3; 0.7%). Women were more likely 
to use herbal therapies (Male: P = 0.056, OR: 0.58 
[0.33–1.01]) as were patients living in an urban area (Rural: 
P = 0.051, odds 2.0 [0.98–4.14]). Although not significant, 
patients using herbal supplements had higher odds of hav-
ing a pretransplant diagnosis of AML/ALL (OR: 1.42 
[0.798–2.55]), cardiovascular risk factors (OR: 1.32 [0.73–
2.39], bone disease (OR: 1.7 [0.95–3.31]), and of seeing a 
psychiatrist (OR: 1.35 [0.49–3.70]). Those using herbal 
supplements had lower odds of being diabetic (OR: 0.83 
[0.33–2.0]) or seeing a social worker (OR: 0.72 [0.21–1.92]) 
or a dietician (OR: 0.45 [0.19–1.04]). Patients were sig-
nificantly less likely to take herbal supplements the more 
prescription medications they took (P = 0.004). There was 
no significant relationship between FACT- BMT and patient’s 
use of herbs.
Vitamin therapy (including minerals and oils)
Self- medication of vitamins (excluding Vitamin D and 
Calcium) was taken by 129 (29.3%) patients, including 
vitamin B (24; 5.4%), vitamin C (33; 7.5%), vitamin E 
(2; 0.5%), fish oil (28; 6.3%), magnesium (15; 3.4%), 
zinc (8; 1.8%), CoQ10 (3; 0.7%), and multivitamins (38; 
8.6%). Calcium was taken by 211 (47.2%) patients and 
vitamin D by 250 (56.7%) patients (Table 4). Patients 
were more likely to take vitamin therapies if they had 
a university degree (OR: 1.36 [0.84–2.19], however, no 
other correlations were identified. Of the 239 patients 
taking vitamin supplements, the total number of supple-
ments (supplement burden) varied, with most patients 
taking one (61; 51%) or two (32; 27%) supplements 
(Table 5).
Variables CAM users (%) Nonusers (%) P value OR (CI)
Doing exercise N = 236 N = 191 0.076 1.45 (0.96–2.19)
Yes (n = 296) 172 (72.9) 124 (64.9)
No (n = 131) 64 (27.1) 67 (35.1)
>3times/Week (199) 124 (73.4) 75 (62.3) 0.049 0.60 (0.36–1.00)
<3 times /Week(90) 45 (26.6) 45 (37.5)
FACT- BMT total score 108.3 (89.7–120) 104.6 (90–119) NS –
Total lee 17.2 (8.5–31.1) 20.85 (10.3–29.9) NS –
Uncertainty score 13.5 (9–17) 14 (10–17) NS –
Factor total 58 (40–68) 50 (30–66) 0.001 –
FACT- BMT, functional assessment of cancer therapy – bone marrow transplant, CAM, complementary and alternative medical therapies. Lee cGVHD 
scale, a valid measure of cGVHD manifestations.
Table 3. Characteristics of CAM users. (Continued)
Table 4. Vitamin supplementation.
Total Vitamin 
Modification
(ex Vit D/ Calcium) Vitamin B Vitamin C Vitamin E Fish oil Magnesium Zinc CoQ10 Multivitamin Calcium Vitamin D
24.7% (109) 5.4% (24) 7.5% (33) 0.5% (2) 6.3% (28) 3.4% (15) 1.8% (8) 0.7% (3) 8.6% (38) 47.8% (211) 56.7% (250)
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Mind–body therapies (including spiritual 
healing)
Mind–body therapies were used by 74 (17.1%) patients, 
including meditation (45; 10.2%), hypnosis/breathing 
exercise (7; 1.6%), spiritual healing (9; 2.0%), yoga (8; 
1.8%), and tai chi (5; 1.1%). Women were more likely 
to use mind–body therapies (22%) versus men (13%). 
Patients with university degrees were significantly more 
likely to use a spiritual and/or mental therapy (P = 0.008 
OR: 2.20 [0.21–3.99]). Likewise, those who saw a 
Psychologist (P = 0.009, OR: 2.19 [1.21–3.99]), Psychiatrist 
(P = 0.015, OR: 2.62 [1.17–5.86]), Physiotherapist 
(P = 0.049, OR: 1.77[0.99–3.14]), Exercise physiologist 
(P = 0.022, OR: 2.48 [1.11–5.51]), or those who exercised 
more than three times per week (P = 0.042, OR: 0.48 
[0.244–0.97]).
Manipulative and body- based therapies
Manipulative and body- based therapies were used by 112 
(26%) patients, including acupuncture (28; 6.3%), chiro-
practic (28; 6.3%), massage (64; 14%), osteopathy (9; 2%), 
physiotherapy (8; 1.8%), and reflexology (6; 1.4%). There 
was a marginal difference in genders seen with 58 (31.2%) 
women and 54 (22%) men using physical therapies. Those 
patients with university degrees were significantly more 
likely to use a manipulative and body- based therapy 
(P = 0.001, OR: 2.24 [1.37–3.67]), whereas those with 
cGVHD also had a greater odds of use (OR: 1.38 [084 
–2.26]).
Traditional Chinese/ayurvedic medicine, 
reiki, and homeopathy
Traditional Chinese/ayurvedic medicine was used by 15 
(3.5%) patients, of which 10 (5.4%) were women and 
5 (2.1%) were men. The patients were significantly less 
likely to take herbal traditional Chinese/ayuredic medicine 
the more prescription medications they took (P = 0.023). 
Reiki (or “energy medicine”) was used by 13 (3%) 
patients, of which 10 (5.4%) were women and 3 (1.2%) 
were men. Homeopathy was used by 13 (3.1%) patients, 
of which 8 (4.4%) were women and 5 (2.1%) were 
men.
Discussion
In this survey of 583 allogeneic Australian HSCT survivors, 
over half (54.2%) used at least one CAM. The most com-
mon CAM therapies used were vitamin therapies (27.3%) 
and manipulative body- based therapies (26.0%), with 
survivors also using mind–body therapies (17.2%), dietary 
modification (13.6%), and herbal supplementation 
(13.5%). This usage is consistent with internationally 
reported CAM usage in cancer patients [6, 11]. The types 
of CAM therapies used by HSCT survivors in our study 
are similar to those used by cancer patients, with vitamins, 
manipulative body- based therapies, and herbal supplemen-
tation used more often than other CAMs.
Few participants (3.1%) reported using homeopathy 
compared to other studies in cancer patients, which report 
usage up to 10% [12]. This may reflect low rates of 
homeopathy usage in Australia compared to the United 
States, and/or the results of recent efforts by the Australian 
NHMRC (National Health and Medical Research Council) 
which released an advisory noting the absence of evidence 
for homeopathy and calling for restrictions on education 
and health insurance subsidies of homeopathy [13]. At 
the same time it is of some concern that only half of 
responders reported taking calcium (47.8%) and vitamin 
D supplements (56.7%), given that these have shown to 
be beneficial in this high- risk patient group [14].
As has been documented in other studies of CAM use, 
both in the general population and in cancer patients [6, 
11, 12], we found a higher proportion of CAM usage by 
women (across all CAM subgroups), those with a uni-
versity education and people living in a major city (which 
may be due to a lack of access to CAM in remote regions 
and smaller towns). We did not see any correlation between 
CAM usage and cGVHD or patient age. Although a cohort 
study using a questionnaire risks selection bias, with such 
a large response rate (76%) of our patient cohort of all 
contactable HSCT survivors over a 13- year period, we 
believe selection bias is minimal and this is an accurate 
proportion of CAM usage.
Given the number of HSCT survivors taking CAM 
therapies, it is important to be aware of the potential 
harms CAM therapies may have, including interactions 
with conventional allogeneic therapies, particularly immu-
nosuppressants and antifungals, as well as risks of 
Table 5. Vitamin supplementation burden.
Number of vitamin 
supplements per patient 
excl calcium +Vit D 1 2 3 4 5 6 7
51% (61) 27% (32) 13% (16) 5% (6) 3% (4) 0 0.8% (1)
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manipulative therapies in patients with underlying bone 
disease and potential harm of overuse of vitamins [15–17]. 
Other direct toxicity with CAM usage including diarrhea 
and vomiting are also a particular concern in transplant 
recipients as they may exacerbate concurrent gastrointestinal 
disease including cGVHD [16]. It is also possible that by 
increasing polypharmacy and the pill burden experienced 
by allogeneic HSCT survivors (a group already taking a 
large number of supportive care medications), CAM thera-
pies may also increase the likelihood of nonadherence [18]. 
Alternatively, several randomized controlled studies, par-
ticularly mind and body interventions were found to have 
potential benefits in this patient group [9]. For example, 
Takatsuka et al. demonstrated a beneficial effect of fish 
oil on the incidence of graft- versus- host disease (GVHD) 
in patients after HSCT [19] and two studies have found 
a significant positive correlation between massage therapy 
and a decline in anxiety and depression level in patients 
after HSCT [20, 21]. Although our subgroup analysis did 
not replicate these results, with no significant differences 
in CGVHD or FACT- BMT scores, the design of the study 
was inadequate for this purpose; rather it has demonstrated 
that a large proportion of HSCT recipients are using these 
CAMs up to 10 years posttransplant.
It is crucial that CAM usage is routinely assessed as 
part of HSCT long- term follow- up (LTFU). While the 
decision to use a CAM always remains the right of the 
patient, it is essential that this decision to do so is informed. 
These results definitively demonstrate a large proportion 
of HSCT survivors are using one or more form of CAM 
therapy. Given the potential benefits demonstrated by small 
studies of specific CAM therapies in this patient group, 
as well as clearly documented therapies with no benefit 
or even toxicity, this result shows there is a large unmet 
need for additional studies to ascertain efficacy and safety 
of CAM therapies in this growing population.
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